Nano Bugle

A window into applied science supported by INL

Collaboration agreement to develop siRNA Therapeutics

PRINT® Particles. Images obtained from Liquida Technologies web site

PRINT® Particles. Images obtained from Liquida Technologies web site

Liquidia Technologies Inc. and Abbott agreed to develop PRINT® nanoparticles for the delivery of siRNA-based therapeutics. With this accord, Liquidia provides certain rights to use the PRINT technology for the development and commercialization of siRNA therapeutics.

With the nanofabrication process called PRINT® (Particle Replication in Non-Wetting Templates) Liquidia Technologies manufactures precise nanoparticles with size, shape, surface chemistry and composition defined.

Liquid is a spin-off from the University of North Carolina-Chapel Hill founded in 2004 that designs and manufactures micro and nanoparticles, and high precision patterned films for applications in the fields of life sciences and materials.

Advertisements

March 30, 2009 - Posted by | Nano News, Nanomedicine | ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: